Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Amrinone-mediated thrombocytopenia.

E L Kinney, J O Ballard, B Carlin

    Scandinavian Journal of Haematology
    |October 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Development of a variable-energy, high-intensity, pulsed-mode ion source for low-energy nuclear astrophysics studies.

    The Review of scientific instruments·2018
    Same author

    Characterisation of the interactive properties of microcrystalline cellulose-carboxymethyl cellulose hydrogels.

    International journal of pharmaceutics·2011
    Same author

    A piece of my mind. To bed with Dad.

    JAMA·2010
    Same author

    Fibrinogen interaction with human platelets: effect of other coagulation factors, prostaglandins and platelet inhibitors.

    Thrombosis research·2010
    Same author

    A piece of my mind. More things in heaven and earth.

    JAMA·2009
    Same author

    A piece of my mind. Provenance.

    JAMA·2009
    Same journal

    Role of iron in the proliferation of the established human tumor cell lines U-937 and K-562: effects of suramin and a lipophilic iron chelator (PIH).

    Scandinavian journal of haematology·1986
    Same journal

    The efficacy and toxicity of VAD in the treatment of myeloma and related disorders.

    Scandinavian journal of haematology·1986
    Same journal

    RES phagocytosis in children with homozygous beta-thalassemia in relation to blood transfusion.

    Scandinavian journal of haematology·1986
    Same journal

    Two allotypes of factor IX present in haemophilia B.

    Scandinavian journal of haematology·1986
    Same journal

    Radioimmunoassay of erythropoietin in chronic uraemia or anephric patients.

    Scandinavian journal of haematology·1986
    Same journal

    Prognostic significance of a morphometric study of lymph node biopsies in chronic lymphocytic leukaemia.

    Scandinavian journal of haematology·1986
    See all related articles

    Amrinone treatment for severe heart failure led to low platelet counts in several patients. Further research is needed to understand why this common side effect occurs.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Hematology

    Background:

    • Severe congestive heart failure (CHF) presents significant therapeutic challenges.
    • Existing treatments for advanced CHF have limitations.
    • Novel cardioactive agents are under investigation.

    Purpose of the Study:

    • To evaluate the safety and efficacy of amrinone in patients with severe congestive heart failure.
    • To identify potential adverse effects associated with amrinone administration.

    Main Methods:

    • A cohort of 12 patients with severe CHF received amrinone.
    • Treatment duration averaged 27.9 days.
    • Platelet counts were monitored throughout the study period.

    Main Results:

    Related Experiment Videos

    • Thrombocytopenia (low platelet count) was observed in 4 patients.
    • A progressive decline in platelet numbers occurred in an additional 3 patients.
    • Adverse hematological effects were noted in a significant proportion of the study group.

    Conclusions:

    • Amrinone administration in severe CHF patients is associated with a notable incidence of thrombocytopenia.
    • The mechanism underlying amrinone-induced platelet reduction requires further investigation.
    • The frequency of these adverse effects warrants careful consideration during clinical use.